Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Gilead Sciences (GILD – Research Report) and keeping the price ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Signaturefd LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 12.1% in the third ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced new research to be presented at The Liver Meeting® 2024, hosted by the ...

Leerink Partnrs upgraded shares of Gilead Sciences (NASDAQ:GILD – Free Report) from a hold rating to a strong-buy rating in a research note issued to investors on Monday, Zacks.com reports. A number ...

The withdrawal of the FDA accelerated approval for locally advanced or metastatic urothelial carcinoma, a type of bladder ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a global biopharmaceutical leader known for its ...

Morgan Stanley notes that Gilead (GILD) and Arcellx’s (ACLX) anito-cel, a BCMA-directed CAR-T therapy in development for relapsed / ...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd. (Otsuka), today announce positive topline interim data from the ongoing Phase 3 clinical trial of ...

Neural Concept, the leading end-to-end 3D AI platform that transforms product design with Engineering Intelligence, has announced the opening of a new office in the United States, located in the New ...

The US Court of Appeals for the Federal Circuit issued its opinion in Allergan USA, Inc. v. MSN Laboratories Private Ltd., No ...